As chronic lymphocytic leukemia (CLL) is characterized by the accumulation of anergic lymphocytes in the blood, lymphatic system, and bone marrow, continuous oral BTK inhibitor administration brings the clonal expansion under manageable control. Here, BTK is linked to B-cell chronic lymphocytic leukemia.